Skip to main content
Journal ArticleOPEN ACCESS

Modified Vaccinia Ankara Virus Vaccination Provides Long-Term Protection against Nasal Rabbitpox Virus Challenge

Clinical and Vaccine Immunology (2016) 23(7) 648-651
DOI: 10.1128/CVI.00216-16
5Citations
Citations of this article
3Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Modified vaccinia Ankara virus (MVA) is a smallpox vaccine candidate. This study was performed to determine if MVA vaccination provides long-term protection against rabbitpox virus (RPXV) challenge, an animal model of smallpox. Two doses of MVA provided 100% protection against a lethal intranasal RPXV challenge administered 9 months after vaccination.

Cite

CITATION STYLE

APA

Jones, D. I., Mcgee, C. E., Sample, C. J., Sempowski, G. D., Pickup, D. J., & Staats, H. F. (2016). Modified Vaccinia Ankara Virus Vaccination Provides Long-Term Protection against Nasal Rabbitpox Virus Challenge. Clinical and Vaccine Immunology, 23(7), 648–651. https://doi.org/10.1128/CVI.00216-16

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free